MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-12-31, AVXL had $29,172K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$29,172K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-12-31
2025-09-30
2025-06-30
Net loss and comprehensive loss
-5,681 -9,827 -36,550
Share based compensation
1,107 3,721 7,828
Incentive and tax receivables
35 -11 -1,629
Prepaid expenses and deposits
-33 -19 -483
Accounts payable
-1,610 -2,491 -2,887
Gain on settlement of accounts payable
--0
Accrued liabilities
-965 -37 -906
Deferred grant income
-0 37
Net cash used in operating activities
-7,151 -8,604 -30,440
Issuance of common shares, net of share issue costs
36,323 9,198 -
Payment for taxes related to cashless exercise of options
-2,707 -
Proceeds from exercise of stock options
-1,264 1,679
Payment for taxes related to cashless exercise of options
---2,262
Issuance of common shares
--0
Net cash provided by financing activities
36,323 10,017 -583
(decrease) increase in cash and cash equivalents during the period
29,172 1,413 -31,023
Cash and cash equivalents at beginning of period
102,577 132,187 -
Cash and cash equivalents at end of period
131,749 102,577 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

ANAVEX LIFE SCIENCES CORP. (AVXL)

ANAVEX LIFE SCIENCES CORP. (AVXL)